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S312 Poster Session II(35% vs. 0, p 5 0.001). Neutrophil and platelet recovery was longer
in the later cohort, although not statistically significant. Cohort 2
had earlier onset for acute GvHD (64 vs. 49 days, p 5 0.048), but
late onset for chronic GvHD (202 vs. 122 days, p5 0.001). Although
cumulative incidence (CI) of grade II-IV acute GvHDwas similar in
two cohorts (cohort 1, 62% vs. cohort 2, 53%), there was trend to-
wards decreased grade III-IV acute GvHD (34 vs.16%, p 5 0.26)
and chronic GvHD (71% vs. 60%, p 5 0.08) in cohort 2. At 2-
year, CI of relapse, non-relapse mortality, leukemia-free and overall
survival were 30%, 30%, 40% and 46%, respectively for all study pa-
tients, and no significant differences noted in cohort 1 and 2 for these
outcomes. Although a trend towards decreased severe acute GvHD
and chronic GvHD is encouraging in the later cohort in this study,
more effective novel strategies are required for prevention of
GvHD, an issue of major concern in older patients.436
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Umbilical cord blood (CB) is utilized with increasing frequency to
restore hematopoiesis in bone marrow transplant patients lacking
a suitableHLA-matched donor. CB transplantation (CBT) is limited
by low cell doses and delays in neutrophil and platelet engraftment.
CB progenitors expanded ex vivo prior to transplantation provide
more rapid hematopoietic and immune reconstitution, as well as
less engraftment failure compared to unmanipulated CB. However,
the relative safety regarding the infusion of ex vivo-expanded CB has
not been systematically examined. Here we review the immediate ad-
verse events (AE) associated with infusion of ex vivo-expanded CB
occurring within 24 hours of infusion in 92 patients enrolled in
two clinical CB expansion trials at the MD Anderson Cancer Center
from February 2004 to May 2010. The median age of enrolled pa-
tients was 42 years (range 3-66), with a predominance of males (n
5 60). 47 patients received a CBT for treatment of acute leukemia.
24 patients had a previous stem cell transplant (22 autologous and
2 allogeneic). The majority of patients (n 5 80) were pre-medicated
prior to transplantation with a combination of diphenhydramine and
steroids. All patients received an unmanipulated CB unit followed by
infusion of the ex vivo-expanded CB product after 1 hour. ABOmis-
matching was observed in 28/89 and 22/89 unmanipulated and ex
vivo-expanded CB products, respectively. The mean volume of the
infusions was 109 mls (range 45-249 mls) for the unmanipulated
CB units and 134 mls (range 39-180 mls) for the expanded product.
A total of twoGrade 1-2 and fiveGrade 3-4 infusion reactions occur-
ring within 24 hours after CBTof both products were observed.This
resulted in an AE rate of 8%. The majority of the AEs manifested as
signs of dyspnea and hypoxia and could be attributed to either vaso-
vagal reactions or volume overload. However, no association with
patient age, disease, previous transplant, total infusion volume, or
ABO incompatibility was observed. In summary, infusion related
toxicities in patients who receive an unmanipulated and ex vivo-ex-
panded double CBT appears relatively low. We conclude that infu-
sion of unmanipulated followed by expanded CB products is a safe
procedure associated with a low probability of inducing severe reac-
tions. We are currently examining the incidence of infusion related
toxicities in patients who have received only unmanipulated CB
products.
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We report the results of a prospective observational clinical trial
with the objective of evaluating HCT outcomes following pre-
HCT therapy with 5-azacitidine. Twenty-three patients seen in
consultation for HCT and medically eligible for a donor search
were enrolled and received 5-azacitidine [75mg/m2 for 7 days every
4 weeks] until a suitable donor was identified. Four did not proceed
to transplant for the following reasons: failure to obtain insurance
approval due to patient age, failure of the pre-HCTorgan evaluation
although a donor was identified, CNS hemorrhage in setting of
chronic anti-coagulation five days prior to HCT admission and
one (62 years) declined HCT as only a HLA-A mismatched donor
was available.Nineteen patients received aHCT following amyeloa-
blative targeted busulfan fludarabine regimen. Median age at HCT
was 57 years (25 – 67). IPSS at diagnosis was Int-1 (2), Int2 (9) and
high (5), CMML1 (1), AMLM6 (1) and not evaluable (NE) (1). Cy-
togenetic risk was good (7), intermediate (5) and poor (7). Three pa-
tients had therapy relatedMDS. Patients received amedian of 4 (1-6)
cycles of 5-azacitidine. Median time from diagnosis (or time of pro-
gression and start of therapy in 2 patients) to HCT infusion was 195
days (107 – 350). Response to 5-azacitidine prior to HCT by the In-
ternational Working Group 2006 criteria included partial response
(8), stable disease (9) and 2 progressed. Two received leukemic in-
duction chemotherapy prior to HCT. IPSS score prior to HCT
was Low (1) Int-1 (6), Int2 (9) and poor (1) and CMML1 (2). Source
of donor cells was peripheral blood siblings (7), matched unrelated
donors (10) and mismatch unrelated donors (2). Median follow-up
from HCT is 440 days (83-696). There are 3 patients who did not
achieve remission (1) or relapsed (2) and 1 of the three remains alive
with active disease. There are 3 non-relapse deaths, 2 due to infection
and 1 due to GVHD. All deaths occurred between days 180 – 262. At
one year OS is 69% (SE 0.12) and DFS is 63% (SE 0.12). In conclu-
sion, pre-HCT 5-azacitidine was well tolerated, provided control of
disease as a bridge toHCT and did not impose additional toxicity af-
ter allogeneic HCT with a promising 1 year progression-free
survival. Controlled trials are needed to determine whether post-
transplant relapse and survival are improved by pre-transplant 5-aza-
citidine.
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COME IN ACUTE LEUKEMIA PATIENTS
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A patient has 30% chance to find an HLA identical sibling donor
(SD) and 40% chance to find a suitable unrelated donor (UD), 40%
of registered patients on international registries relapse or die before
finding a donor. We evaluated the outcome in acute leukemia (AL)
patients, whether they had anHLA identical SD, an UD or no donor
(ND) after registration on France Greffe de Moelle (FGM) registry,
either transplanted later or not. Secondary objectives were to evalu-
ate the impact of intervals diagnosis-allo-HSCT, donor finding-allo-
HSCT, registration-allo-HSCT, on OS and EFS. We analyzed 251
AL patients, 117 (47%) males and 134 females, median age at diag-
nosis 40 years [16-66], 177 (71%) AML and 75 ALL. Seventy six
(30%) patients had an available SD and received allo-HSCT within
a median time of 3.5 months (0.5–43) and 38 (15%) had SD but were
not transplanted due to early relapse and/or death. For patients with
no available SD, a registration on FGM registry was done, 137 pa-
tients were registered after a median interval of 2.3 months (0.4-
135) from diagnosis, 33 (13%) patients did not find any donor and
they received the standard of care; 104 (41%) patients found an
UD or UCB unit after a median time of 1.6 months (0.3-26): 86
with UD of which only 60 have been transplanted within a median
time of 2.3 months (0.4–14), 18 with UCB of which only 17 were
transplanted. Among transplanted patients, 113 (74%) were in CR,
40 in\ CR. Fifty (33%) received PBSC, 86 (57%) received BM
and 17 (10%) UCB units. For conditioning, 56 (37%) were RIC
